Artiva (ARTV) news
Recent news
Artiva Biotherapeutics Inc: quarterly EPS $-0.63
Artiva Biotherapeutics Inc. (Nasdaq: ARTV) reported a quarterly earnings per share (EPS) of -$0.63 for the second quarter of 2026, slightly missing the consensus estimate of -$0.64 . The company continues to operate at a loss, consistent with its status as a pre-revenue clinical-stage biotechnology…
AInvest Wire · Aug 6, 2026Artiva Biotherapeutics - May offer up to $400 mln in securities - SEC filing
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) has filed with the U.S. Securities and Exchange Commission (SEC) for a potential offering of up to $400 million in securities, according to a recent filing. The company, a clinical-stage biotechnology firm focused on developing cell therapies for…
AInvest Wire · Aug 6, 2026Artiva Biotherapeutics announces new employee inducement grants under Nasdaq listing rule 5635(c)(4)
Artiva Biotherapeutics has announced the issuance of new employee inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). These grants are part of the company’s ongoing efforts to attract and retain qualified personnel, as permitted under the rule, which allows for the approval of…
AInvest Wire · Jul 17, 2026H.C. Wainwright raises target price to $35 from $33
H.C. Wainwright has raised its price target for Artiva Biotherapeutics (NASDAQ:ARTV) to $35 from $15, while maintaining a Buy rating. The stock currently trades at $10.89, with a market capitalization of $269 million. The upgrade follows the release of initial clinical trial results for Artiva’s…
AInvest Wire · Jun 2, 2026Artiva Biotherapeutics announces pricing of upsized $167M IPO
AInvest Wire · Jul 19, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.